BMO Capital analyst Evan Seigerman maintains Gilead Sciences (NASDAQ:GILD) with a Outperform and raises the price target from $94 to $102.
BMO Capital Maintains Outperform on Gilead Sciences, Raises Price Target to $102
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.